Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Oncology and palliative care indexChapter sections
Purpose and principlesIndications, selection and cautionsMethod and interpretationClinical next stepsRisks, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Cancer staging, grading and performance status

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Purpose and principles

Distinguish anatomical stage, pathological grade and functional performance status, establish each with the correct evidence, and use them with biology and patient priorities rather than as interchangeable labels.

Staging provides a common language for disease extent, prognosis, treatment selection and audit. TNM describes the primary tumour, regional nodal disease and distant metastasis, but definitions are site- and edition-specific. Some cancers use dedicated systems or clinically important risk groups. Clinical stage is assigned from pre-treatment information; pathological stage follows adequate surgery and histology. Treatment can change appearances, so post-treatment assessment should not erase the original burden.

Grade is a pathology construct based on differentiation, architecture, mitoses, necrosis or defined molecular features depending on tumour type. It estimates behaviour within that disease but cannot be compared casually across cancers. Performance status is separate again: ECOG or WHO categories reflect activity and self-care. It contributes to treatment safety and trial eligibility but may improve when reversible cancer complications are treated.

The correct workflow defines the tumour type, consults the current staging manual and dataset, selects site-specific imaging, obtains tissue, then discusses stage, grade, biomarkers, comorbidity, organ reserve and preferences in the MDT. The resulting plan should specify curative, disease-control or symptom-focused intent and note any stage uncertainty that further testing could resolve.

Key points

  • Stage describes anatomical extent, usually primary tumour, regional nodes and distant metastasis; the applicable TNM edition and tumour-specific system must be named.
  • Clinical stage uses examination, imaging and biopsy information before definitive surgery, while pathological stage incorporates resection findings and may be more precise.
  • Grade describes microscopic differentiation, proliferation or tumour-specific biological aggressiveness and is not another word for stage.
  • Performance status summarises functional impact and treatment tolerance but can be worsened by reversible infection, anaemia, obstruction, pain or dehydration.
  • Staging tests should be selected because they change treatment intent, field or operation; indiscriminate imaging creates incidental findings and delay.
  • A higher stage does not automatically mean no meaningful treatment, and a low stage does not guarantee favourable biology.
  • Restaging after neoadjuvant treatment must distinguish baseline clinical extent from treatment-response findings and use the correct prefix conventions.
  • Record evidence and uncertainty, not just a number, so future teams can reconstruct how the decision was made.

Indications, selection and cautions

Local disease

The tumour remains confined to its organ or immediate structures, but resectability still depends on site-specific anatomy and biology.

Regional nodal disease

Nodes in the defined drainage basin may change operation, radiotherapy field or systemic treatment; enlarged nodes are not automatically malignant.

Distant metastasis

Disease in a non-regional organ or node usually changes stage and intent, although oligometastatic pathways exist for selected cancers.

High-grade morphology

Poor differentiation, high mitotic activity or tumour-specific high-grade features suggest aggressive biology independent of anatomical spread.

Reduced performance status

Limited self-care or time out of bed may reflect tumour burden, comorbidity or a reversible complication that should be treated before final eligibility decisions.

Method and interpretation

  1. 01
    Tumour-specific staging imagingFirst step
    Why
    Define local, nodal and distant extent before treatment.
    Interpretation and limitations
    Use the modality and anatomical coverage recommended for the cancer; suspicious findings may need targeted confirmation when they alter curative intent.
  2. 02
    Histopathological grade
    Why
    Classify microscopic biological aggressiveness using the relevant dataset.
    Interpretation and limitations
    Report the tumour-specific grading system and sample limitations; biopsy grade may underrepresent heterogeneous resection tissue.
  3. 03
    Clinical TNM assignment
    Why
    Record pre-treatment extent from examination, imaging and pathology.
    Interpretation and limitations
    Apply the current edition and site rules, documenting cT, cN and cM evidence rather than an unsupported stage-group label.
  4. 04
    Pathological TNM assignment
    Why
    Refine stage after adequate definitive surgery and nodal assessment.
    Interpretation and limitations
    Margin status and treatment response are reported separately; neoadjuvant therapy requires the proper post-treatment prefix and baseline stage preservation.
  5. 05
    ECOG or WHO performance status
    Why

Clinical next steps

01DefineEstablish baseline extentFirst stepDefinitiveCancer is histologically confirmed or strongly suspected and definitive planning begins.+
  1. 1Name the tumour subtype, staging system and edition, then identify which anatomical findings could change treatment intent.
  2. 2Complete the site-specific imaging and tissue pathway, confirming equivocal distant lesions when the consequence would be major.
  3. 3Assign clinical stage with the supporting evidence and preserve this baseline through any neoadjuvant treatment.
02IntegrateAdd grade and functional reserveAnatomical stage is available but treatment choice remains uncertain.+
  1. 1Review grade, biomarkers, organ function, comorbidity and patient-reported function alongside ECOG or WHO performance status.
  2. 2

Risks, monitoring and follow-up

  • Keep the staging system, edition, date and evidence in the MDT record so later changes are interpretable.
  • Update stage only when new evidence justifies it; do not silently convert suspicion into confirmed metastasis.
  • Reassess performance status after treating reversible complications and before each major treatment decision.
  • Track weight, frailty, organ function and patient-reported activity because numerical performance status misses important reserve.
  • At progression, compare the same target lesions and modality where possible, while investigating discordant clinical deterioration.

Special situations

Stage and grade differ

A small local tumour can be high grade, while extensive disease may retain lower-grade morphology; both dimensions inform prognosis.

Imaging suspicion is evidence

Radiological metastasis may be sufficient in some contexts but needs tissue when an alternative diagnosis would preserve a curative route.

Performance can recover

Drainage, analgesia, transfusion, infection treatment or endocrine correction can change function and reopen treatment choices.

Edition matters

TNM definitions evolve, so a stage group without tumour site and edition can be ambiguous in audit and follow-up.

Intent needs words

Curative, adjuvant, disease-control and symptom-directed goals should be stated explicitly rather than inferred from stage alone.

Common pitfalls

  1. 01

    Using stage and grade interchangeably.

  2. 02

    Assigning TNM without naming the edition.

  3. 03

    Calling enlarged nodes malignant without context.

  4. 04

    Declaring metastasis from an indeterminate lesion that would alter cure.

  5. 05

    Treating performance status as fixed.

  6. 06

    Erasing baseline stage after neoadjuvant therapy.

  7. 07

    Letting a stage number replace shared decision-making.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Oncology and palliative careOriginal SBA

Stage versus grade

A small organ-confined tumour has marked pleomorphism, necrosis and high mitotic activity on pathology. Which statement best distinguishes its assessment?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Oncology and palliative care topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • Royal College of Pathologists cancer datasetsTumour-specific grade, stage elements, margins and structured pathological reporting.
  • NHS England cancer programmeMultidisciplinary staging and timely treatment planning across national cancer services.
  • NICE shared decision making recommendationsIntegrating evidence, function, uncertainty and individual priorities into treatment choices.
  • NICE suspected cancer recommendationsDiagnostic and imaging routes that establish baseline cancer extent.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Describe current activity and self-care for treatment planning.
Interpretation and limitations
Assess the person's usual recent function and identify reversible causes; clinician estimates can differ from patient experience.
Treat reversible deterioration such as infection, effusion, obstruction, pain, anaemia or hypercalcaemia before declaring a person unable to receive treatment.
  • 3Discuss curative and non-curative options with absolute benefits, burdens and alternatives rather than using performance status as a solitary gate.
    • 03RestageAssess after treatment or recurrenceNeoadjuvant therapy ends, disease recurs or progression is suspected.+
    1. 1Use the disease-specific response and imaging method, compare with baseline and distinguish scar or treatment inflammation from viable tumour.
    2. 2Report post-treatment pathological stage and response without deleting the original clinical stage that determined therapy.
    3. 3At recurrence, document sites, tempo, symptoms and new biopsy or molecular needs before redefining treatment intent.